In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.